Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Gene Fusions Make Some Pan-Negative Melanomas Sensitive to MEK Inhibitors

By BiotechDaily International staff writers
Posted on 16 Jan 2014
Image: Scanning electron micrograph of a melanoma cell. BRAF fusion genes in pan-negative melanomas may render them sensitive to MEK inhibitors (Photo courtesy of Vanderbilt University).
Image: Scanning electron micrograph of a melanoma cell. BRAF fusion genes in pan-negative melanomas may render them sensitive to MEK inhibitors (Photo courtesy of Vanderbilt University).
Cancer researchers have identified a class of fusion genes that drive melanoma metastasis in the 35% of these skin cancers that lack the previously known driver mutations.

According to senior author Dr. Jeffrey A. Sosman, professor of medicine at Vanderbilt University (Nashville, TN, USA) "About 35% of melanomas are, as of today, considered "pan-negative,” which means they are devoid of any previously known driver mutations in the genes BRAF, NRAS, KIT, GNAQ, and GNA11."

Dr. Sosman and his colleagues used a targeted next-generation sequencing (NGS) assay (FoundationOne) and targeted RNA sequencing to search for potential drug targets in a series of pan-negative melanoma specimens.

FoundationOne, the first clinical product from the biotech company Foundation Medicine (Cambridge, MA, USA), is the first commercially available targeted sequencing assay utilizing clinical grade next-generation sequencing (NGS) in routine cancer specimens. This test identifies all classes of genomic alterations (including copy number alterations, insertions, deletions, and rearrangements) in hundreds of cancer-related genes. It complements traditional cancer treatment-decision tools and often expands treatment options by matching each patient with targeted therapies that are relevant to the molecular changes in their tumor.

The investigators reported in the December 15, 2013, issue of the journal Clinical Cancer Research that they had found fusions between the bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthetase 1 gene (PAPSS1) and the V-raf murine sarcoma viral oncogene homolog B1 gene (BRAF) and between the BRAF gene and the tripartite motif-containing 24 gene (TRIM24).

Both classes of BRAF fusions activated the MAPK signaling pathway. The investigators treated fusion gene-bearing cells either with the BRAF inhibitor vemurafenib or with trametinib, an inhibitor of MEK, a protein in the MAPK signaling pathway. Results showed that signaling induced by the BRAF fusions was not responsive to vemurafenib but could be inhibited by trametinib, which implied that the fusions could make melanoma cells harboring them sensitive to MEK inhibitors.

"Performing a sophisticated analysis called targeted next-generation sequencing, it appears that about 8% of pan-negative melanomas have BRAF fusions," said Dr. Sosman. "Our results are important because they obviously suggest that there probably are other, as yet unidentified, molecular changes that make these melanomas susceptible to drugs that are available right now."

This study was funded in part by "Stand up to Cancer" (Pasadena, CA, USA), an organization that raises funds to accelerate the pace of cancer research in order to get new therapies to patients quickly and save lives now.

Related Links:
Vanderbilt University
Foundation Medicine
Stand up to Cancer


Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.